… Editing Oligonucleotides (EONs) recruit endogenous ADAR to make single nucleotide changes to RNA in a highly … Gerard Platenburg, Chief Innovation Officer at ProQR added, “We are the first to show evidence of RNA editing … an endogenously expressed RNA editing system called ADAR, which it can direct to change an Adenosine (A) to an …
… will provide an overview of ProQR’s proprietary ADAR-mediated Axiomer RNA editing technology platform, … for therapeutic development of editing oligonucleotides. Additionally, the presentation will detail AX-0810, the … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are …
… to execute on our strategy.” Recent Progress Continue to advance AX-0810 for patients suffering from cholestatic … cardiovascular risk. ProQR plans to present and publish additional preclinical data from these two pipeline programs … Chardan Genetic Medicines Conference panel discussion on “ ADAR RNA Editing: Unlocking New Therapeutic Opportunities ”. …
… initial pipeline targets expected in late 2022/early 2023 Additional pivotal trial recommended by EMA for sepofarsen … (MAA). In light of this feedback and in order to continue advancement of the portfolio of ophthalmic product … may selectively enter additional partnerships designed to advance and capture the full potential value of the platform. …
… upfront payment and equity investment ProQR is eligible to additionally receive up to approximately $ 1. 25 billion in … oligonucleotides, or EONs, designed to recruit endogenous ADAR enzymes (Adenosine Deaminases Acting on RNA) to a selected target …
… been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in … the vision loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s scientific advisory board. LEIDEN, the Netherlands, May 09, 2018 (GLOBE …